@entity43 is the most dangerous complication following the administration of gonadotropins. There is no preventive and pharmacological intervention that can fully prevent development of this syndrome. The best strategy to reduce the incidence of the condition is to identify the @entity1 at risk before ovarian stimulation and to recognize potential predictors. A history of @entity43 is an important risk factor for recurrence of the syndrome. The risk of the syndrome is evident with elevated gonadotropin dosages and with the use of gonadotropin releasing hormone agonists. @entity1 chorionic gonadotropin is the main risk factor. The combination of pretreatment diagnosis of @entity3610 and @entity53 of 4500 pg/ mL gives higher prediction rates for the risk factor. Serum concentration of inhibin is not a reliable predictor of the syndrome. Recent evaluation of antim  llerian hormone as a reliable predictor candidate, @entity7 with cadherin as indicators of vascular permeability, and detection of mutations in the follicular stimulating hormone receptor as predictors of severity offer new insights in the prognosis of the syndrome. Identification of these prognostic markers in @entity1 at risk would be very useful for prevention of the syndrome prior to the appearance of symptoms.

New insights in prediction of XXXX .

@entity43 :: ('MESH:D010051', 'Disease') :: ['Ovarian hyperstimulation syndrome', 'ovarian hyperstimulation'] @entity1 :: ('9606', 'Species') :: ['patients', 'Human'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary disease'] @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian hyperstimulation syndrome']
